Destination therapy with left ventricular assist devices: for whom and when?

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Cardiac transplantation is the primary therapy for advanced heart failure.
• Improved cardiovascular care has increased the number of patients ineligible for transplant due to age or comorbidities.
• Durable mechanical circulatory support is emerging as a key treatment for this population.

Purpose of the Study:

• To review the evolution and application of durable mechanical circulatory support, specifically destination therapy (DT) left ventricular assist devices (LVADs).
• To identify patient selection criteria and optimal timing for DT LVAD therapy.
• To discuss the adverse event profile associated with DT LVADs.

Main Methods:

• Review of landmark clinical trials (e.g., REMATCH, Heart Mate II) and registry data (INTERMACS).
• Analysis of patient characteristics, warning signs, and symptoms predictive of clinical decline.
• Evaluation of the safety and efficacy of continuous-flow intracorporeal LVADs.

Main Results:

• Left ventricular assist devices (LVADs) have evolved into durable, continuous-flow devices for permanent support.
• Landmark trials and registries provide insights into patient selection and timing for DT LVAD.
• Identifying pre-decline warning signs aids in selecting candidates for DT LVAD.

Conclusions:

• Destination therapy LVAD is a viable option for advanced heart failure patients not candidates for transplant.
• Ongoing data collection and technological advancements will refine patient selection and implantation timing.
• The adverse event burden of DT LVAD therapy requires careful consideration alongside medical management.